AML, LYT-200 and PureTech

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.
PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class
PureTech Drug Gets FDA Fast-Track Designation for Leukemia
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid leukemia, as well as a separate fast-track designation for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.
PureTech receives FDA fast track designation for leukemia treatment
(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia. The designation aims to expedite the development and regulatory review of drugs addressing serious conditions with unmet medical needs.
PureTech Says FDA Grants Fast Track Designation For LYT-200 In Acute Myeloid Leukemia
Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company ...
pharmaphorum8d
PureTech challenges Roche's Esbriet in head-to-head IPF trial
PureTech meanwhile is also exploring the use of LYT-100 in other indications, including as a treatment for respiratory complications of long COVID and breast cancer-related, upper limb secondary ...
Hosted on MSN24d
PureTech sees success in Phase IIb Pulmonary Fibrosis trial
Boston-situated clinical-stage biotherapeutics company PureTech’s Phase IIb trial of deupirfenidone met all primary and secondary endpoints, slowing lung degeneration in patients with idiopathic ...
Yahoo Finance25d
PureTech's Lung Disease Candidate Slowed Lung Function Decline In Idiopathic Pulmonary Fibrosis Patients
PureTech Health plc (NASDAQ:PRTC) stock is up on Monday, after the company announced results from ELEVATE IPF Phase 2b trial of deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis (IPF).
Business Wire25d
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the ...
The two doses of deupirfenidone were chosen based on PureTech’s Phase 1 data, which showed that a 550 mg TID dose of deupirfenidone provided approximately equivalent drug exposure to pirfenidone ...
TMCnet4d
PureTech Appoints UBS as UK Corporate Broker
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), is pleased to announce that it has appointed UBS as its UK Corporate Broker.
FierceBiotech25d
PureTech's lung fibrosis drug slows decline in phase 2 trial
PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis (IPF). The med, called deupirfenidone, is a deuterated form of Roche ...